1. Bombardier C, Laine L, Reicin A, Shapiro D, Burgos-Vargas R, Davis B, Day R, Ferraz MB, Hawkey CJ, Hochberg MC, Kvien TK, Schnitzer TJ for the VIGOR Study Group (2000) Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. N Engl J Med 343:1520–1528
2. Chan A-W, Tetzlaff JM, Altman DG, Laupacis A, Gøtzsche PC, Krleža-Jeric K, Hróbjartsson A, Mann H, Dickersin K, Berlin J, Doré C, Parulekar W, Summerskill W, Groves T, Schulz K, Sox H, Rockhold FW, Rennie D, Moher D (2013) SPIRIT 2013 statement: defining standard protocol items for clinical trials. Ann Intern Med 158:200–207
3. Coronary Drug Project Research Group (1973) The coronary drug project: design, methods, and baseline results. Circulation 47(Suppl I):I-1–I-50
4. Crewdson J Fraud in breast cancer study, Chicago tribune, 13 March 1994
5. Curfman GD, Morrissey S, Drazen JM (2005) Expression of concern: Bombardier et al., comparison of upper gastrointestinal toxicity of Rofecoxib and naproxen in patients with rheumatoid arthritis. N Engl J Med 343:1520–1528. N Engl J Med 2005;353:2813–2814